Trusted Resources: News & Meetings
Latest announcements and gatherings
Experimental MPS 1 Therapy Shows Biomarker Activity, Improved Function
REGENXBIO presented results from its ongoing Phase I/II trial of RGX-111, an investigational one-time gene therapy for people with Mucopolysaccharidosis Type I (MPS I). The data, presented at the 18th annual WORLDSymposium, represented six patients diagnosed with severe MPS I who were treated with RGX-111.
Mucopolysaccharidosis Type I is a rare, genetic condition that can affect many parts of the body. The condition stems from a mutation in the IDUA gene which provides instructions for producing an enzyme that is involved in the breakdown of large sugar molecules. In people with MPS I, the gene reduces or completely eliminates the enzymes needed for the breakdown of large sugar molecules, leading to the accumulation of these molecules in cells called lysosomes, whose function is to digest and recycle molecules. The lysosomes become enlarged, causing significant issues in multiple organs including decline in central nervous system (CNS) functioning.
BookmarkRelated Content
-
COVID-19 and MPS Patientshttps://www.youtube.com/watch?v=euwZ_vDW...
-
A Guide to Understanding MPS II (Hunter Syndrome)MPS II belongs to a group of inherited m...
-
[Pharmacological Property, Mechanism of Action and Clinical Study Results of Pabinafusp Alfa (Genetical Recombinatio...Mucopolysaccharidosis type II (MPS II) i...
-
Challenges of Enzyme Replacement Therapy for Sanfilippo SyndromeWhat Is Enzyme Replacement Therapy?Enzym...
-
The First Mucopolysaccharidosis Type VII in a Taiwanese Girl: A Case Report and Review of the LiteratureThe present study included the first cas...
-
Paul Orchard, MDDr. Paul Orchard is the Medical Director...
-
A 22 Year Old Rotherham Man, no Longer Walk Up His StairsA Yorkshire community has launched a fun...
Powered by
